The aim of this technology assessment, commissioned by NICE through the NIHR SR Programme as part of the NICE’s Single Technology Appraisal process, was to review the submission received from Shire Pharmaceuticals on the clinical and cost-effectiveness of Atezolizumab monotherapy (Tecentriq®) for untreated advanced non-small-cell lung cancer (NSCLC). The main source of evidence submitted by Shire Pharmaceuticals, consisted of a Phase III, muticentre, open-label RCT (IMpower110). The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for this technology appraisal and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from Shire Pharmaceuticals and the ERG’s critique, NICE has now released appropriate clinical guidance.
Atezolizumab is recommended, within its marketing authorisation, as an option for untreated metastatic NSCLC in adults if:
- their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells
- their tumours do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations and
- the company provides atezolizumab according to the commercial arrangement.
For more information see: https://www.nice.org.uk/guidance/ta705
Miriam Brazzelli; email@example.com